Mt. Jackson firm buys German lab company
StageBio acquires TPL Path Labs
Mt. Jackson-based preclinical and clinical archiving company StageBio announced Tuesday it has acquired Freiburg, Germany-based TPL Path Labs.
Terms of the acquisition were not disclosed.
StageBio provides GLP-compliant (good laboratory practice) necropsy, histology, pathology and specimen archiving services for both preclinical and clinical research. The combined company will offer other services including histopathology, molecular pathology, toxicology and digital image analysis, and it will employ 175 people, including 30 pathologists.
“The addition of TPL Path Labs to StageBio represents a significant step in our global strategy to support researchers with the broadest range of quality solutions at every stage of discovery through clinical development,” StageBio CEO Tom Galati said in a statement. “The expertise and sophisticated capabilities of the TPL team integrate perfectly with StageBio’s, enabling us to deliver solutions with a combination of depth, breadth and quality that is unmatched in the markets we serve.”
The acquisition will add a GLP/GCLP-compliant lab facility and staff in Germany to the StageBio’s existing six GLP-compliant lab facilities and two GLP specimen archive sites in the U.S., reducing the need to ship study materials overseas, according to the company.
“Becoming part of StageBio is great news for TPL Path Labs’ customers across Europe, Australia and Asia,” Ayse Bal, TPL path labs general manager, said in a statement. “By expanding our capabilities, scale and geographic reach, the combined organization enables us to respond even more rapidly and effectively to our customers’ needs.”